{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:21:17Z","timestamp":1791404477511,"version":"4.3.3"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Soft tissue sarcoma is a rare and aggressive disease with a 40 to 50% metastasis rate. The limited efficacy of traditional approaches with surgery, radiation, and chemotherapy has prompted research in novel immunotherapy for soft tissue sarcoma. Immune checkpoint inhibitors such as anti-CTLA-4 and PD-1 therapies in STS have demonstrated histologic-specific responses. Some combinations of immunotherapy with chemotherapy, TKI, and radiation were effective. STS is considered a \u2018cold\u2019, non-inflamed tumor. Adoptive cell therapies are actively investigated in STS to enhance immune response. Genetically modified T-cell receptor therapy targeting cancer testis antigens such as NY-ESO-1 and MAGE-A4 demonstrated durable responses, especially in synovial sarcoma. Two early HER2-CAR T-cell trials have achieved stable disease in some patients. In the future, CAR-T cell therapies will find more specific targets in STS with a reliable response. Early recognition of T-cell induced cytokine release syndrome is crucial, which can be alleviated by immunosuppression such as steroids. Further understanding of the immune subtypes and biomarkers will promote the advancement of soft tissue sarcoma treatment.<\/jats:p>","DOI":"10.3389\/fonc.2023.1150765","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T10:54:18Z","timestamp":1678791258000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas"],"prefix":"10.3389","volume":"13","author":[{"given":"Gyuhee","family":"Seong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","volume-title":"Soft tissue and bone tumors: WHO classification of tumours, vol. 3","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Von Mehren","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.2.120","article-title":"Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis","volume":"86","author":"Scholl","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1674113","DOI":"10.1080\/2162402X.2019.1674113","article-title":"Prognostic profiling of the immune cell microenvironment in ewing\u00b4s sarcoma family of tumors","volume":"8","author":"Stahl","year":"2019","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041080","article-title":"Systemic inflammatory indices in second-line soft tissue sarcoma patients: Focus on Lymphocyte\/Monocyte ratio and trabectedin","volume":"15","author":"Fausti","year":"2023","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13046-021-01963-1","article-title":"The potential role of the extracellular matrix in the activity of trabectedin in UPS and l-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models","volume":"40","author":"De Vita","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials","volume":"13","author":"Italiano","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11015","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts","volume":"37","author":"Burgess","year":"2019","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1200\/JCO.2020.38.15_suppl.11511","article-title":"A multicenter phase II study of nivolumab +\/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): results of expansion cohorts","volume":"38","author":"Chen","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221093973","article-title":"Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives","volume":"14","author":"Vanni","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000512828","article-title":"Long-term remission with Ipilimumab\/Nivolumab in two patients with different soft tissue sarcoma subtypes and no PD-L1 expression","volume":"14","author":"Zhou","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025262","article-title":"Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report","volume":"100","author":"Luo","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13728","article-title":"Metastatic myxofibrosarcoma with durable response to temozolomide followed by atezolizumab: A case report","volume":"26","author":"Lambden","year":"2021","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.725484","article-title":"Case report: Response to regional melphalan via limb infusion and systemic PD1 blockade in recurrent myxofibrosarcoma: A report of 2 cases","volume":"11","author":"Bartlett","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680503","article-title":"Radiation-induced immunity and toxicities: The versatility of the cGAS-STING pathway","volume":"12","author":"Constanzo","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"11520","DOI":"10.1200\/JCO.2020.38.15_suppl.11520","article-title":"SAINT: results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161]","volume":"38","author":"Gordon","year":"2020","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft part sarcoma: a single-arm,phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1451","article-title":"Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen NY-ESO-1 but not MAGE-A1 or CT7","volume":"94","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.133","article-title":"The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas","volume":"26","author":"Hemminger","year":"2013","journal-title":"Mod Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/imt.14.98","article-title":"Adoptive cell therapy for sarcoma","volume":"7","author":"Mata","year":"2015","journal-title":"Immunotherapy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma","volume":"8","author":"D\u2019Angelo","year":"2018","journal-title":"Cancer Discovery"},{"key":"B47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2020.38.15_suppl.102","article-title":"Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors","volume":"38","author":"Hong","year":"2020","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.1200\/JCO.2021.39.15_suppl.11504","article-title":"SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma","volume":"39","author":"D\u2019Angelo","year":"2021","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00307-7","article-title":"TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential","volume":"28","author":"Poorebrahim","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"LB","DOI":"10.1158\/1538-7445.AM2019-LB-147","article-title":"Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas","volume":"79","author":"Navai","year":"2019","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-11126-y","article-title":"A TCR-based chimeric antigen receptor","volume":"7","author":"Walseng","year":"2017","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00257","article-title":"TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens","volume":"11","author":"Akatsuka","year":"2020","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T cells in solid tumors: Blueprints for building effective therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000157","article-title":"Toxicities associated with adoptive T-cell transfer for cancer","volume":"21","author":"Yang","year":"2015","journal-title":"Cancer J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-modified T cells: Toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor- infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/CJI.0000000000000355","article-title":"Expanded tumor-infiltrating lymphocytes from soft tissue sarcoma have tumor-specific function","volume":"44","author":"Mullinax","year":"2021","journal-title":"J Immunother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"A640","DOI":"10.1016\/j.jval.2014.08.2307","article-title":"Early cost-effectiveness modeling for tumor infiltrating lymphocytes (TIL) -treatment versus ipilimumab in metastatic melanoma patients","volume":"17","author":"Retel","year":"2014","journal-title":"Value Health"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): An intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"58085817","DOI":"10.1158\/1078-0432.CCR-19-1025","article-title":"First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1","volume":"25","author":"Somaiah","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1419068","article-title":"The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid\/round cell liposarcoma patients","volume":"17","author":"Pollack","year":"2018","journal-title":"Expert Rev Vaccin"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1847846","DOI":"10.1080\/2162402X.2020.1847846","article-title":"A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral-based prime-boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1","volume":"9","author":"Somaiah","year":"2020","journal-title":"Oncoimmunology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03452","article-title":"Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1","volume":"40","author":"Chawla","year":"2021","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200203000-00012","article-title":"Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma","volume":"24","author":"Matsuzaki","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1303","article-title":"Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study","volume":"38","author":"Dagher","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02370.x","article-title":"SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese musculoskeletal oncology group","volume":"103","author":"Kawaguchi","year":"2012","journal-title":"Cancer Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"TPS11593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS11593","article-title":"TTI-621-03: A phase I\/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS)","author":"Chawla","year":"2022","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.953555","article-title":"The emerging role of cancer nanotechnology in the panorama of sarcoma","volume":"10","author":"Mercatali","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.1945167","article-title":"Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy","volume":"28","author":"Chen","year":"2021","journal-title":"Drug Deliv"},{"key":"B78","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MAJ.0b013e31823e62e5","article-title":"The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine","volume":"344","author":"Yang","year":"2012","journal-title":"Am J Med Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25062","article-title":"Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma","volume":"61","author":"Wagner","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2013.11.006","article-title":"Immunomodulation of macrophages by methylglyoxal conjugated with chitosan nanoparticles against sarcoma-180 tumor in mice [published correction appears in cell immunol. 2014 mar-Apr;288(1-2):66]","volume":"287","author":"Chakrabarti","year":"2014","journal-title":"Cell Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"950.e28.e28","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1042.e10.e10","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0202-3","article-title":"Characteristics of mismatch repair deficiency in sarcomas","volume":"32","author":"Doyle","year":"2019","journal-title":"Mod Pathol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000369906","article-title":"Absence of microsatellite instability in soft tissue sarcomas","volume":"82","author":"Campanella","year":"2015","journal-title":"Pathobiology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147518","article-title":"Molecular determinants of soft tissue sarcoma immunity: Targets for immune intervention","volume":"22","author":"Tazzari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001458","article-title":"Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients","volume":"9","author":"Starzer","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1150765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T11:17:13Z","timestamp":1678879033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1150765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":87,"alternative-id":["10.3389\/fonc.2023.1150765"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1150765","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1150765"}}